-
Something wrong with this record ?
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model
O. Uher, K. Hadrava Vanova, K. Petrlakova, R. Labitt, R. Lencova, A. Frejlachova, J. Ye, H. Wang, M. Masarik, J. Zenka, Z. Zhuang, K. Pacak
Language English Country Netherlands
Document type Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Intramural
Grant support
Z01 HD008735
Intramural NIH HHS - United States
ZIA HD008735
Intramural NIH HHS - United States
- MeSH
- B-Lymphocytes * immunology MeSH
- Pheochromocytoma * immunology therapy MeSH
- Immunotherapy * methods MeSH
- Disease Models, Animal MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Adrenal Gland Neoplasms * immunology therapy MeSH
- Tumor Necrosis Factor-alpha MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Research Support, N.I.H., Intramural MeSH
Immunotherapy represents a revolutionary advancement in cancer treatment, which has traditionally focused on T cells; however, the role of B cells in cancer immunotherapy has gained interest because of their role in antigen presentation, antibody production, and cytokine release. In this study, we examined the role of B cells in previously developed intratumoral MBTA therapy (mannan-BAM, TLR ligands, and anti-CD40 antibody) in murine models of MTT pheochromocytoma. The results indicated that B cells significantly enhance the success of MBTA therapy, with wild-type mice exhibiting a lower tumor incidence and smaller tumors compared with B cell-deficient mice. Increased IL-6 and TNF-alpha levels indicated severe inflammation and a potential cytokine storm in B cell-deficient mice. Neutralization of TNF-alpha ameliorated these complications but resulted in increased tumor recurrence. The results highlight the important role of B cells in enhancing the immune response and maintaining immune homeostasis during MBTA therapy. Our findings offer new insights into improving therapeutic outcomes.
BIOCEV 1st Faculty of Medicine Charles University Vestec 25250 Czech Republic
Department of Physiology Faculty of Medicine Masaryk University Brno 62500 Czech Republic
Neuro Oncology Branch National Cancer Institute NIH Bethesda 20892 MD USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010512
- 003
- CZ-PrNML
- 005
- 20250429135113.0
- 007
- ta
- 008
- 250415s2025 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.beem.2024.101941 $2 doi
- 035 __
- $a (PubMed)39278811
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Uher, Ondrej $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda 20892, MD, USA. Electronic address: ondrej.uher@nih.gov
- 245 10
- $a Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model / $c O. Uher, K. Hadrava Vanova, K. Petrlakova, R. Labitt, R. Lencova, A. Frejlachova, J. Ye, H. Wang, M. Masarik, J. Zenka, Z. Zhuang, K. Pacak
- 520 9_
- $a Immunotherapy represents a revolutionary advancement in cancer treatment, which has traditionally focused on T cells; however, the role of B cells in cancer immunotherapy has gained interest because of their role in antigen presentation, antibody production, and cytokine release. In this study, we examined the role of B cells in previously developed intratumoral MBTA therapy (mannan-BAM, TLR ligands, and anti-CD40 antibody) in murine models of MTT pheochromocytoma. The results indicated that B cells significantly enhance the success of MBTA therapy, with wild-type mice exhibiting a lower tumor incidence and smaller tumors compared with B cell-deficient mice. Increased IL-6 and TNF-alpha levels indicated severe inflammation and a potential cytokine storm in B cell-deficient mice. Neutralization of TNF-alpha ameliorated these complications but resulted in increased tumor recurrence. The results highlight the important role of B cells in enhancing the immune response and maintaining immune homeostasis during MBTA therapy. Our findings offer new insights into improving therapeutic outcomes.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a feochromocytom $x imunologie $x terapie $7 D010673
- 650 _2
- $a myši $7 D051379
- 650 12
- $a nádory nadledvin $x imunologie $x terapie $7 D000310
- 650 12
- $a B-lymfocyty $x imunologie $7 D001402
- 650 12
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a TNF-alfa $7 D014409
- 650 _2
- $a ženské pohlaví $7 D005260
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, N.I.H., Intramural $7 D052060
- 700 1_
- $a Hadrava Vanova, Katerina $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda 20892, MD, USA. Electronic address: katerina.hadravavanova@nih.gov
- 700 1_
- $a Petrlakova, Katerina $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda 20892, MD, USA; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno 62500 Czech Republic. Electronic address: katerina.petrlakova@med.muni.cz
- 700 1_
- $a Labitt, Rachael $u Research Animal Management Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda 20892, MD, USA. Electronic address: rachael.labitt@nih.gov
- 700 1_
- $a Lencova, Radka $u Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice 37005, Czech Republic. Electronic address: lencor00@prf.jcu.cz
- 700 1_
- $a Frejlachova, Andrea $u Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice 37005, Czech Republic. Electronic address: frejla00@prf.jcu.cz
- 700 1_
- $a Ye, Juan $u Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda 20892, MD, USA. Electronic address: juan.ye@nih.gov
- 700 1_
- $a Wang, Herui $u Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda 20892, MD, USA. Electronic address: herui.wang@nih.gov
- 700 1_
- $a Masarik, Michal $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno 62500 Czech Republic; Department of Physiology, Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic; BIOCEV (Biotechnology and Biomedicine Center in Vestec), First Faculty of Medicine, Charles University, Vestec 25250, Czech Republic. Electronic address: masarik@med.muni.cz
- 700 1_
- $a Zenka, Jan $u Department of Medical Biology, Faculty of Science, University of South Bohemia, Ceske Budejovice 37005, Czech Republic. Electronic address: jzenka@prf.jcu.cz
- 700 1_
- $a Zhuang, Zhengping $u Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda 20892, MD, USA. Electronic address: zhengping.zhuang@nih.gov
- 700 1_
- $a Pacak, Karel $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda 20892, MD, USA. Electronic address: karel@mail.nih.gov
- 773 0_
- $w MED00013220 $t Baillière's best practice & research. Clinical endocrinology & metabolism $x 1878-1594 $g Roč. 39, č. 1 (2025), s. 101941
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39278811 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135109 $b ABA008
- 999 __
- $a ok $b bmc $g 2311711 $s 1247593
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 39 $c 1 $d 101941 $e 20240911 $i 1878-1594 $m Baillière's best practice & research. Clinical endocrinology & metabolism $n Best Pract Res Clin Endocrinol Metab $x MED00013220
- GRA __
- $a Z01 HD008735 $p Intramural NIH HHS $2 United States
- GRA __
- $a ZIA HD008735 $p Intramural NIH HHS $2 United States
- LZP __
- $a Pubmed-20250415
